Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $11.86 Average Target Price from Brokerages
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been given an average rating of “Hold” by the ten analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. […]
More Stories
IKEA’s Affordable Smart Sensor in the Spotlight of 2026 Gadget Launch Lineup
IKEA has long dominated the world of affordable furnishings, but its recent push into smart home-tech is grabbing eyeballs. The...
All-American Season 8 Confirmed? Get Updates on Release Date, Cast, and Trailer
Since its first release in 2018, All-American has evolved from a simple high school football drama to family issues and...
“I Want to Contribute in a Way that Feels Fully in my Integrity…” AI Safety Leader Leaves Anthropic
Mrinank Sharma, the head of Anthropic’s safeguards research team, publicly announced his resignation on the 9th of this month. His...
Bubba Wallace Balances His New Sponsorship While Facing Racism Criticism
If you have an interest in car racing, you must have heard the name of Bubba Wallace. He is a...
Alphabet Stays Quiet on Google-Apple AI Partnership During Earnings Call
Alphabet’s recent earnings call left investors hanging when it came to questions about its new AI deal with Apple. The...
US Sanctions Hezbollah Finance Operatives
By Jackson Richman The United States sanctioned financial operatives and entities linked to Hezbollah, the Departments of State and Treasury...